Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds

[Image: see text] Ponatinib is a multikinase inhibitor that is used to treat chronic myeloid leukemia patients harboring mutated ABL1(T315I) kinase. Due to the potent inhibition of FLT3, RET, and fibroblast growth factor receptors (FGFRs), it is also being evaluated against acute myeloid leukemia (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Larocque, Elizabeth, Chu, Elizabeth Fei Yin, Naganna, Nimmashetti, Sintim, Herman O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033671/
https://www.ncbi.nlm.nih.gov/pubmed/32095692
http://dx.doi.org/10.1021/acsomega.9b03223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033671/
https://www.ncbi.nlm.nih.gov/pubmed/32095692
http://dx.doi.org/10.1021/acsomega.9b03223

Ejemplares similares